A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks. Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic. PZA at the dose and schedule employed has insignificant activity in this population.